Constipation - Pipeline Review, H2 2018

  • ID: 4590342
  • Report
  • 103 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Ardelyx Inc
  • Dong-A ST Co Ltd
  • EA Pharma Co Ltd
  • Johnson & Johnson
  • MallInckrodt Plc
  • MORE
Constipation - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2018, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

Report Highlights:

This latest pipeline guide Constipation - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 8, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Ardelyx Inc
  • Dong-A ST Co Ltd
  • EA Pharma Co Ltd
  • Johnson & Johnson
  • MallInckrodt Plc
  • MORE
Introduction

Report Coverage

Constipation - Overview

Constipation - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Constipation - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Constipation - Companies Involved in Therapeutics Development

Allergan Plc

Ardelyx Inc

Braintree Laboratories Inc

Dong-A ST Co Ltd

EA Pharma Co Ltd

Ironwood Pharmaceuticals Inc

Johnson & Johnson

MallInckrodt Plc

NGM Biopharmaceuticals Inc

RaQualia Pharma Inc

Sanwa Kagaku Kenkyusho Co Ltd

SK Biopharmaceuticals Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Synthetic Biologics Inc

Vanda Pharmaceuticals Inc

Yuhan Corp

Zensun (Shanghai) Sci & Tech Co Ltd

Constipation - Drug Profiles

5-BIOP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AJG-555 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLI-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLI-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DA-6886 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSP-6952 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

J-027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaclotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaclotide DR2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lovastatin MR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lubiprostone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naronapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prucalopride succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relenopride hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00000010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SK-1202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tenapanor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-12852 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZS-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Constipation - Dormant Projects

Constipation - Discontinued Products

Constipation - Product Development Milestones

Featured News & Press Releases

Jun 03, 2018 : New Data on the Cardiovascular Safety of Prucalopride Presented at 2018 Digestive Disease Week Annual Meeting

May 03, 2018 : Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS (linaclotide) Patent Litigation

Apr 30, 2018 : FDA Responds to Mallinckrodt’s Supplemental New Drug Application for New Indication for AMITIZA (Lubiprostone)

Mar 05, 2018 : U.S. FDA Accepts New Drug Application for Prucalopride (SHP555) for Chronic Idiopathic Constipation

Jan 16, 2018 : Sun Pharma Announces Settlement of Patent Litigation for Generic Linzess in US

Jan 03, 2018 : Ardelyx Successfully Completes T3MPO-3 Safety Extension Study of Tenapanor for IBS-C

Nov 27, 2017: Application for Marketing and Manufacturing Approval of Chronic Constipation Treatment AJG555 Was Filed in Japan

Oct 16, 2017: Allergan to Present New Data on Gastrointestinal Drug Candidate Linaclotide at the World Congress of Gastroenterology at ACG

Oct 16, 2017: Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling

Oct 11, 2017: Ardelyxs Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018

Sep 28, 2017: Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation

Sep 11, 2017: Astellas Submits Supplemental New Drug Application for Approval of Additional Indication of "Linaclotide" for Patients with Chronic Constipation in Japan

Jun 27, 2017: Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation

May 12, 2017: Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C

May 09, 2017: Ironwood Pharmaceuticals Presents Data Further Elucidating Linaclotide's Effect on Pain at Digestive Disease Week

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Constipation, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Constipation - Pipeline by Allergan Plc, H2 2018

Constipation - Pipeline by Ardelyx Inc, H2 2018

Constipation - Pipeline by Braintree Laboratories Inc, H2 2018

Constipation - Pipeline by Dong-A ST Co Ltd, H2 2018

Constipation - Pipeline by EA Pharma Co Ltd, H2 2018

Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Constipation - Pipeline by Johnson & Johnson, H2 2018

Constipation - Pipeline by MallInckrodt Plc, H2 2018

Constipation - Pipeline by NGM Biopharmaceuticals Inc, H2 2018

Constipation - Pipeline by RaQualia Pharma Inc, H2 2018

Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2018

Constipation - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018

Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018

Constipation - Pipeline by Synthetic Biologics Inc, H2 2018

Constipation - Pipeline by Vanda Pharmaceuticals Inc, H2 2018

Constipation - Pipeline by Yuhan Corp, H2 2018

Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2018

Constipation - Dormant Projects, H2 2018

Constipation - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Constipation, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Ardelyx Inc
  • Braintree Laboratories Inc
  • Dong-A ST Co Ltd
  • EA Pharma Co Ltd
  • Ironwood Pharmaceuticals Inc
  • Johnson & Johnson
  • MallInckrodt Plc
  • NGM Biopharmaceuticals Inc
  • RaQualia Pharma Inc
  • Sanwa Kagaku Kenkyusho Co Ltd
  • SK Biopharmaceuticals Co Ltd
  • Sumitomo Dainippon Pharma Co Ltd
  • Synthetic Biologics Inc
  • Vanda Pharmaceuticals Inc
  • Yuhan Corp
  • Zensun (Shanghai) Sci & Tech Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll